| Literature DB >> 27911119 |
Michael J Kelley1,2,3, Gautam Jha4, Debra Shoemaker2, James E Herndon2, Lin Gu2, William T Barry2,5, Jeffrey Crawford1,2, Neal Ready1,2.
Abstract
The Src pathway in activated in about one-third of non-small cell lung cancer (NSCLC) tumors. Dasatinib has Src-inhibitor activity. We examined the activity of dasatinib in 37 patients with advanced, previously treated NSCLC. Among the 29 patients who underwent pre-treatment biopsy for RNA biomarker analysis, 25 were treated with dasatinib 70 mg twice daily. There were no responses. Five patients discontinued treatment due to toxicity. Three patients had minor biopsy-related pneumothoraces. Given the lack of responses, no biomarkers were analyzed. Dasatinib 70 mg twice daily does not have activity nor is it well tolerated in unselected patients with advanced stage, previously treated NSCLC.Entities:
Keywords: Non-small cell lung cancer; Src; gene expression
Mesh：
Substances：
Year: 2016 PMID： 27911119 DOI： 10.1080/07357907.2016.1253710
Source DB: PubMed Journal: Cancer Invest ISSN： 0735-7907 Impact factor: 2.176